Reference-based pricing of prescription drugs
McLaughlin, P.R.
Canadian Journal of Cardiology 13(1): 31-32
1997
ISSN/ISBN: 0828-282X PMID: 9039062 Document Number: 478055
Document emailed within 1 workday
Related Documents
McGregor, M. 1998: Coverage of drug costs: reference-based pricing Canadian Journal of Cardiology 14(5): 666-668Silverman, M.; Lydecker, M. 1974: Prescription drug pricing by hospital pharmacies: a preliminary study American Journal of Hospital Pharmacy 31(9): 870-875
Zite, N.B.; Barry, A.D.; Wallace, L.S. 2014: Variation in prescription contraceptive pricing across Florida ZIP code income groups Contraception 89(1): 54-56
1997: A position paper on drug-pricing strategies for prescription pharmaceuticals in Canada. Canadian Cardiovascular Society Canadian Journal of Cardiology 13(1): 33-45
Simons, L.A.; Tett, S.; Simons, J.; Lauchlan, R.; McCallum, J.; Friedlander, Y.; Powell, I. 1992: Multiple medication use in the elderly. Use of prescription and non-prescription drugs in an Australian community setting Medical Journal of Australia 157(4): 242-246
Boland, P. 2014: The promise and the pitfalls of reference pricing Managed Care 23(5): 36-38
López de Landache, I.E.; Braceras Izaguirre, L.; Echeto García, A.; Gardeazabal Romillo, M.J.é; Acevedo Heranz, P. 2013: Efficiency in the prescription of drugs. Impact of a health policy: automatic change to prescription by active ingredient Revista de Enfermeria 36(11): 49-52
Persson, I.; Adami, H.O.; Norell, S.E.; Westerholm, B.; Wiholm, B.E. 1991: Evaluation of a prescription based record-linkage model for epidemiological studies of long-term adverse effects of drugs--with special regard to combined oral contraceptives European Journal of Clinical Pharmacology 40(5): 489-493
Borrell, J. 2007: Pricing and patents of HIV/AIDS drugs in developing countries Applied Economics 39(4): 505-518
Borrell, J. 2007: Pricing and patents of HIV/AIDS drugs in developing countries Applied Economics 39(4): 505-518
Lopert, R.; Lang, D.L.; Hill, S.R.; Henry, D.A. 2002: Differential pricing of drugs: a role for cost-effectiveness analysis? Lancet 359(9323): 2105-2107
Johnson, K.F. 1987: Pricing hospital services. Developing a cost base for pricing Topics in Health Care Financing 14(1): 16-25
Wichmann, R.; Clark, R. 2006: Developing a defensible pricing strategy. Hospital pricing is a science, not an art Healthcare Financial Management: Journal of the Healthcare Financial Management Association 60(10): 72
Degkwitz, R. 1980: Psychotropic drugs. Sense and nonsense in the prescription of sedating, psycholeptic and hypnotic drugs Zfa. Zeitschrift für Allgemeinmedizin 56(2): 77-83
Lamy, P.P.; Kitler, M.E. 1971: Untoward effects of drugs. I. (Including non-prescription drugs) Diseases of the Nervous System 32(1): 17-23
Novelli, T. 2009: The US market: moving towards greater evidence-based pricing Medical Device Technology 20(3): 50-51
Chan, H.L.; Stern, R.S.; Arndt, K.A.; Langlois, J.; Jick, S.S.; Jick, H.; Walker, A.M. 1990: The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients Archives of Dermatology 126(1): 43-47
Imai, S. 1975: Action mechanism of anti-hypertensive drugs, with special reference to beta blocking drugs Nihon Jinzo Gakkai Shi 17(7): 674-677
Sonne, J.; Faber, O. 2004: Economic prescription of drugs Ugeskrift for Laeger 166(18): 1695
Thrasher, J.E. 1981: Informed consent - prescription of drugs Journal of the Florida Medical Association 68(10): 811